Sign up to save your podcasts
Or
Share February 2016 issue: Too many options, too little choice in COPD?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
February 2016 issue: Too many options, too little choice in COPD?
In this podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the proliferation of new drugs for managing COPD; review two new lipid-lowering drugs (evolocumab and alirocumab) from a new class (proprotein convertase subtilisin/kexin type 9 inhibitors); and consider total ankle joint replacement. The DTB podcast is recorded monthly to coincide with the release of the print issue of DTB. Read all the articles featured here: http://dtb.bmj.com/content/54/2.toc
View all episodes
By [email protected]In this podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the proliferation of new drugs for managing COPD; review two new lipid-lowering drugs (evolocumab and alirocumab) from a new class (proprotein convertase subtilisin/kexin type 9 inhibitors); and consider total ankle joint replacement. The DTB podcast is recorded monthly to coincide with the release of the print issue of DTB. Read all the articles featured here: http://dtb.bmj.com/content/54/2.toc